La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Biotricity Gestione

Gestione criteri di controllo 2/4

Biotricity's Il CEO è Waqaas Al-Siddiq, nominato in Jul2014, e ha un mandato di 10.08 anni. la retribuzione annua totale è $ 1.25M, composta da 38.3% di stipendio e 61.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 3.46% delle azioni della società, per un valore di $ 314.13K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.8 anni e 7 anni.

Informazioni chiave

Waqaas Al-Siddiq

Amministratore delegato

US$1.3m

Compenso totale

Percentuale dello stipendio del CEO	38.3%
Mandato del CEO	10.2yrs
Proprietà del CEO	3.5%
Durata media del management	6.9yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Waqaas Al-Siddiq rispetto agli utili di Biotricity?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	US$1m	US$480k	-US$15m
Dec 31 2023	n/a	n/a	-US$15m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	US$1m	US$480k	-US$20m
Dec 31 2022	n/a	n/a	-US$21m
Sep 30 2022	n/a	n/a	-US$23m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	US$887k	US$480k	-US$30m
Dec 31 2021	n/a	n/a	-US$30m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	US$891k	US$390k	-US$16m
Dec 31 2020	n/a	n/a	-US$16m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	US$2m	US$390k	-US$11m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	US$2m	US$360k	-US$9m
Dec 31 2018	n/a	n/a	-US$10m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	US$1m	US$310k	-US$9m

Compensazione vs Mercato: La retribuzione totale di Waqaas ($USD 1.25M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Waqaas è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Waqaas Al-Siddiq (39 yo)

10.2yrs

Mandato

US$1,254,153

Compensazione

Dr. Waqaas Al-Siddiq, PhD, has founded Biotricity Inc.(formerly known as iMedical Innovations Inc.) in July 2014 and has been its Chairman, President and Chief Executive Officer since July 2014. Dr. Al-Sid...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Waqaas Al-Siddiq	Founder	10.2yrs	US$1.25m	3.46% $ 324.3k
S. Ayanoglou	Chief Financial Officer	6.9yrs	US$562.00k	1.21% $ 113.2k
Amjad Talpur	Senior Director of Operations	no data	Nessun dato	Nessun dato
George Nikopoulos	Director of Business Development	no data	Nessun dato	Nessun dato
Matt Zabel	Vice President of Sales & Strategy	no data	Nessun dato	Nessun dato
Amir Ali	Chief Development Officer	no data	Nessun dato	Nessun dato
Fareeha Siddiqui	Senior Vice President of Healthcare Solutions	less than a year	Nessun dato	Nessun dato

6.9yrs

Durata media

Gestione esperta: Il team dirigenziale di BTCY è esperto e expertise (durata media dell'incarico 6.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Waqaas Al-Siddiq	Founder	10.2yrs	US$1.25m	3.46% $ 324.3k
John Simpson	Chair of Scientific & Medical Alliance Board and Chair of Science Alliance Board	4.5yrs	Nessun dato	Nessun dato
Daniel Sands	Member of the Board of Advisors	8.3yrs	Nessun dato	Nessun dato
Ronald McClurg	Independent Director	2.3yrs	US$32.62k	0.16% $ 14.6k
David Rosa	Independent Director	8.3yrs	US$60.00k	1.32% $ 123.6k
J. Rice	Member of the Board of Advisors	8.3yrs	Nessun dato	Nessun dato
John Rother	Member of the Board of Advisors	8.3yrs	Nessun dato	Nessun dato
Thomas Nelson	Member of the Board of Advisors	8.3yrs	Nessun dato	Nessun dato
Donald Cross	Member of Scientific & Medical Alliance Board	5.8yrs	Nessun dato	Nessun dato
Edward Lazaga	Member of Scientific & Medical Alliance Board	5.8yrs	Nessun dato	Nessun dato
Imran Mohiuddin	Member of Scientific & Medical Alliance Board	5.8yrs	Nessun dato	Nessun dato
Radoslaw Kiesz	Member of Scientific & Medical Alliance Board	5.8yrs	Nessun dato	Nessun dato

7.0yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BTCY sono considerati esperti (durata media dell'incarico 7 anni).

Biotricity Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Less than half of directors are independent

Less than half of directors are independent

Biotricity Announces Management Changes

High number of new directors

High number of new directors

Recent updates

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Biotricity, Inc. announced a financing transaction

Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023)

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity Releases Another Groundbreaking Product: Biotres Pro

New major risk - Market cap size

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device

Biotricity, Inc. has completed a Follow-on Equity Offering.

New major risk - Financial position

First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023)

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications

Biotricity Regains Nasdaq Listing Compliance

Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023

Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022)

Third quarter 2023 earnings: Revenues exceed analyst expectations

Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price

Consensus revenue estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$3.83

Less than half of directors are independent

Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

Less than half of directors are independent

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity Announces Management Changes

Biotricity, Inc.: A First Take

Biotricity, Inc. announced delayed annual 10-K filing

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022

High number of new directors

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

High number of new directors

Biotricity: Capital Raise Leads To Buying Opportunity

Biotricity Common Stock Deleted from Other OTC

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022

Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021

Biotricity, Inc. announced that it has received $9.5575 million in funding

Biotricity Announces New Solution for Personal Heart Management with Bioheart

Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres

Biotricity Inc. Announces Launch of Its Bioflux® Direct Program

Biotricity, Inc. announced a financing transaction

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media